Cancer drug combo trial for kids halted early
NCT ID NCT04544995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a combination of two drugs, niraparib and dostarlimab, in children and teens (ages 6 months to 17 years) with solid tumors that had come back or were not responding to treatment. The goal was to find a safe dose and see if the drugs could shrink tumors. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Birmingham, B4 6NH, United Kingdom
-
GSK Investigational Site
Sutton, SM2 5PT, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple screening program could transform cancer aftercare
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can engineered immune cells tackle childhood sarcoma?
- Can a simple text message transform cancer care?